6-{5-[4-(4-fluorophenylsulfanyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one | 438634-29-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 6-{5-[4-(4-fluorophenylsulfanyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one
• 英文别名: 6-[5-[[4-(4-fluorophenyl)sulfanylpiperidin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one
• CAS: 438634-29-8
• 化学式: C₂₂H₂₂FN₃O₃S
• 分子量: 427.499
• InChiKey: HYOPVBIOWBLYPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  88.5
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists
  申请人：——

  公开号：US20030018021A1

  公开（公告）日：2003-01-23

  Described are piperidines of Formula I 1 and pharmaceutically acceptable salts thereof. The compounds of Formula I are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, stroke, cerebral ischemia, central nervous system disorders, depression, trauma, hypoglycemia, neurodegenerative disorders, anxiety, migraine headache, convulsions, Parkinson's disease, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, pain, especially chronic pain, neuropathic pain, or surgical pain, or urinary incontinence.

  描述了式I的哌啶类化合物及其药用盐。式I的化合物是NMDA受体通道复合物的拮抗剂，可用于治疗脑血管疾病，如中风、脑缺血、中枢神经系统疾病、抑郁症、创伤、低血糖、神经退行性疾病、焦虑、偏头痛、抽搐、帕金森病、氨基糖苷类抗生素引起的听力损失、精神病、青光眼、巨细胞病毒性视网膜炎、阿片类耐受性或戒断症状、疼痛，尤其是慢性疼痛、神经病性疼痛或手术疼痛，以及尿失禁。
• PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS
  申请人：Warner-Lambert Company LLC

  公开号：EP1345935A2

  公开（公告）日：2003-09-24
• US6642256B2
  申请人：——

  公开号：US6642256B2

  公开（公告）日：2003-11-04
• [EN] PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS<br/>[FR] DERIVES DE PIPERIDINE EN TANT QU'ANTAGONISTES VIS-A-VIS DE N-METHYL-D-ASPARTATE (NMDA), AVEC SELECTIVITE EN TERMES DE SOUS-TYPE
  申请人：WARNER LAMBERT CO

  公开号：WO2002050070A2

  公开（公告）日：2002-06-27

  Described are piperlines of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) ar antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, stroke, cerebral ischemia, central nervous system disorders, depression, trauma, hypoglycemia, neurodegenerative disorders, anxiety, migraine headache, convulsions, Parkinson's disease, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retitins, opioid tolerance or withdrawal, pain, especially chronic pain, neuropathic pain, or surgical pain, or urinary incontinence.